Search Results - Neal D Shore

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
    Experience with degarelix in the treatment of prostate cancer

    Experience with degarelix in the treatment of prostate cancer by Neal D. Shore

    Published 2013-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36

    Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs... by Neal D. Shore

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer

    Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer by Fred Saad, Neal D. Shore

    Published 2021-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Clinical use of nadofaragene firadenovec-vncg

    Clinical use of nadofaragene firadenovec-vncg by Badrinath R. Konety, Neal D. Shore, Grannum R. Sant

    Published 2024-09-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia

    Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia by Bilal Chughtai, Sirikan Rojanasarot, Kurt Neeser, Dmitry Gultyaev, Stacey L. Amorosi, Neal D. Shore

    Published 2021-05-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia

    Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia by Bilal Chughtai, Sirikan Rojanasarot, Kurt Neeser, Dmitry Gultyaev, Stacey L. Amorosi, Neal D. Shore

    Published 2021-05-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility

    Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility by E. David Crawford, Neal D. Shore, Daniel P. Petrylak, Celestia S. Higano, Charles J. Ryan

    Published 2017-05-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists

    Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists by Mohamad Moussa, Mohamad Abou Chakra, Neal D. Shore, Athanasios Papatsoris, Yasser Farahat, Michael A. O’Donnell

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Mechanism of action of nadofaragene firadenovec-vncg

    Mechanism of action of nadofaragene firadenovec-vncg by Vikram M. Narayan, Joshua J. Meeks, Jørn S. Jakobsen, Neal D. Shore, Grannum R. Sant, Badrinath R. Konety

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

    A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local th... by Martin Gleave, Brad Rosbrook, Stephen J Freedland, Qi Shen, Jennifer Sugg, Gabriel P Haas, Neal D Shore

    Published 2021-08-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Pharmacokinetic and pharmacodynamic comparison of subcutaneous intramuscular leuprolide acetate formulations in male subjects

    Pharmacokinetic and pharmacodynamic comparison of subcutaneous intramuscular leuprolide acetate formulations in male subjects by Daniel Saltzstein, Neal D. Shore, Judd W. Moul, Franklin Chu, Raoul Concepcion, Stephan de la Motte, John A. McLane, Stuart Atkinson, Alex Yang, E. David Crawford

    Published 2018-02-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

    Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials by Neil M Schultz, Neal D Shore, Simon Chowdhury, Laurence H Klotz, Raoul S Concepcion, David F Penson, Lawrence I Karsh, Hongbo Yang, Bruce A Brown, Arie Barlev, Scott C Flanders

    Published 2018-10-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

    Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials by Neil M. Schultz, Neal D. Shore, Simon Chowdhury, Laurence H. Klotz, Raoul S. Concepcion, David F. Penson, Lawrence I. Karsh, Hongbo Yang, Bruce A. Brown, Arie Barlev, Scott C. Flanders

    Published 2018-09-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context

    Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerR... by Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal

    Published 2023-06-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

    The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma by Daniel P. Petrylak, Lawrence Fong, Charles G. Drake, Mark N. Stein, Douglas G. McNeel, Ravi A. Madan, James L. Gulley, Neil H. Bander, Tomasz M. Beer, Stacey Harrelson, Philip W. Kantoff, William K. Oh, David J. Peace, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Johannes Vieweg

    Published 2016-12-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

    Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi) by Herjan J.T. Coelingh Bennink, Jeroen A. van Moorselaar, E. David Crawford, Erik P.M. Roos, Diederik M. Somford, Ton A. Roeleveld, Tjard D. de Haan, Harm H.E. van Melick, Yacov Reisman, Yvette Zimmerman, Gonnie van Osta, Jan Krijgh, Neal D. Shore, Fred Saad, Andrew V. Schally, Frans M.J. Debruyne

    Published 2021-06-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: